Cost-effectiveness of Ombitasvir/Paritaprevir/Ritonavir, Dasabuvir+Ribavirin for US Post-Liver Transplant Recurrent Genotype 1 HCV. [electronic resource]
Producer: 20161221Description: 515-21 p. digitalISSN:- 1478-3231
- 2-Naphthylamine
- Anilides -- economics
- Antiviral Agents -- economics
- Carbamates -- economics
- Cost-Benefit Analysis
- Cyclopropanes
- Drug Costs
- Drug Therapy, Combination
- Female
- Genotype
- Hepacivirus -- drug effects
- Hepatitis C -- diagnosis
- Humans
- Lactams, Macrocyclic
- Liver Transplantation -- adverse effects
- Macrocyclic Compounds -- economics
- Male
- Markov Chains
- Middle Aged
- Models, Economic
- Phenotype
- Proline -- analogs & derivatives
- Recurrence
- Ribavirin -- economics
- Risk Factors
- Ritonavir -- economics
- Sulfonamides -- economics
- Time Factors
- Treatment Outcome
- United States
- Uracil -- analogs & derivatives
- Valine
- Viral Load
- Virus Activation -- drug effects
No physical items for this record
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.